Article Sidebar

Submitted
May 1, 2021
Published
May 1, 2021
Download
PDF
Statistic
Read Counter : 77 Download : 39

Main Article Content

Abstract

Aim


This study is aimed to assess the prescription pattern in DM patients with co morbid condition, because prescription pattern could lead to worsening of disease and increased risk of complications. The specific and general aspects of diabetic patients including the available dosage forms, to patients, drug interactions observed and common co morbities seen in diabetic patients, all add to difficulties facing by the practitioner who treats them. Due to the above reasons the study was designed to help minimize the prescription errors, render safe dosage regimen, by carefully monitoring the patientsglyceminc control and other responses towards therapy, finally improving the quality of life.


Methodology


This is a prospective observational study conducted over a period of six months using questionnaires as a tool. The study was conducted at Nephrology ward of AWARE GLOBAL HOSPITAL LB. NAGAR. Patients who admitted to the general ward of the hospital during a six-month period from October 2016 to March 2017 are enrolled.


Results


Based on inclusion and exclusion criteria, 98 patients were selected from the inpatient department over a period of 6 months for the present study. Among 98 patients The gender distribution found in the following study was males (64%) and females (36%), the age distribution was found to be 25-35 yrs (4%),35-45yrs (12%),45-55 yrs (24%), 55-65yrs (35%), 65-75 yrs (17%) ,75-85 yrs (8%). Of the total 98 cases enrolled the co morbid conditions found were Hypertension (76%), hypothyroidism (16%) and chronic kidney disease (15%). A total of 464 drugs were prescribed during the study period. 102 (22%) antidiabetics, 72(15.5%) antihypertensives, 59(12.72%) multivitamins, 46 (9.9%) antiplatelets, 20(4.31%) statins and 165(35.5%) miscellaneous drugs were prescribed.


Conclusion


The final report drawn from a total of 98 cases with the primary condition “DIABETES MELLITUS TYPE -II” the major co-morbid condition found was HYPETENSION (76 cases) in the study population.


The standard therapy which showed good control for the condition Diabetes + Hypertension given was:



  1. Ca+2 channel blockers (22.45% usage) eg. Amlodipine

  2. β-Blockers (15.31%) eg. Metoprolol

  3. Biguanides (43%) eg. Metformin

  4. Human Mixtard Insulin (25%)

Article Details

How to Cite
PadalaSrikanth, D. Karthik Kumar, G. NarenderMallapuraju Rahul, SamaTabassum, & Dr. P. Sneha pharm. D. (2021). Prescription pattern of diabetes mellitus with comorbid condition. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(3), 339-347. https://doi.org/10.61096/ijrpp.v6.iss3.2017.339-347
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. World health organization: Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World health organization; 1999
  2. [2]. World health organization: Diabetes – Factsheet. 2012.
  3. [3]. Shobana R, Augustine C, Ramachandran A, Vijay V. Improving psychosocial care: The Indian experience. Diabetes Voice 2005; 50(1):19-21.
  4. [4]. Chew LD: The impact of low health literacy on diabetes outcomes. Diabetes Voice49(3), 2004, 30-32.
  5. [5]. American Association of Diabetes Educators: Self-Care Behaviors. Diabetes education 34, 2008, 445-449.
  6. [6]. Abduelkarem AR, SackvilleMA. Changes of some Health Indicators in Patients with Type 2 Diabetes: A Prospective Study in three Community Pharmacies in Sharjah. Ljm 4(1), 2009, 31-36.
  7. [7]. Shipra Jain,” A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines” PMCID: PMC4394586.
  8. [8]. Mohan, V, Epidemiology of type 2 diabetes: Indian scenario “Indian Journal of Medical Research; New Delhi” 125.3 2007, 217-30.
  9. [9]. RajeshwariShastry Assistant Professor, Department of Pharmacology, Kasturba Medical College Mangalore, “Usage of diuretics among diabetic-hypertensive patients.” Asian Journal of Medical Sciences 6(2), 2015.
  10. [10]. DAS.S, Sri SaiAditya Institute of Pharmaceutical Sciences and Research, “Age and sex related prevalence and drug utilization pattern in the management of type 2 diabetes mellitus and its comorbidity with cardiovascular diseases.” Indian Journal Of Pharmaceutical Sciences. 2015, 478
  11. [11]. SUPRATIM DATT Department of pharmacology, Sikkim Manipal Institute of Medical Sciences,
  12. “Antihypertensive drug use in patients having comorbid diabetes: cross-Sectional prescription pattern study in a tertiary care hospital.” Asian Journal Of Pharmaceutical and Clinical Research 3(4), 2010.
  13. [12]. Msberry, “Insulin in combination with other diabetes medication is associated with less alzheimer neuropathology.” Neurology 17(10), 2008, 750-757.
  14. http://www.neurology.org/content/71/10/750.short
  15. [13]. Andre J. Scheen “Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.” Published in: Diabetes/Metabolism Research & Reviews (2010).
  16. [14]. AkshayaSrikanthBhagavathula, “Prevalence of potential drug-drug interactions among internal medicine ward in University of Gondar Teaching Hospital.” Asian pacific journal of tropical biomedicine, Volume 4. Supplement 2014, S204-S208.
  17. [15]. Lukashevich.V “Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.” 2013 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. date of final acceptance 2013.
  18. [16]. AR. Pandey “Prevalence and Determinants of Comorbid Diabetes and Hypertension in Nepal: Evidence from NCD Risk Factors STEPS Survey Nepal 2013.” 1 Nepal Health Research Council (NHRC) JNHRC Vol. 13(29), 2015.
  19. [17]. Park-Wyllie Pharm-D, “Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults” at www.nejm. org on March 1, 2006, THE NEW ENGLAND JOURNAL OF MEDICINE.
  20. [18]. Hayward R “Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes” This article was updated on 2015, at NEJM.org. THE NEW ENGLAND JOURNAL OF MEDICINE. Copyright © 2015 Massachusetts Medical Society.
  21. [19]. Fried, M.D, “Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy”. N Engl J Med; 369, 2013, 1892-903. DOI: 10.1056/NEJMoa1303154 Copyright © 2013 Massachusetts Medical Society. THE NEW ENGLAND JOURNAL OF MEDICINE.
  22. [20]. Wanner C, M.D “Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes” Copyright © 2016 Massachusetts Medical Society, THE NEW ENGLAND JOURNAL OF MEDICINE.
  23. [21]. Haller H M.D “Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes” Copyright © 2016 Massachusetts Medical Society, THE NEW ENGLAND JOURNAL OF MEDICINE.
  24. [22]. Lind M, M.D, “Glycemic Control and Excess Mortality in Type 1 Diabetes” Copyright © 2016 Massachusetts Medical Society, THE NEW ENGLAND JOURNAL OF MEDICINE.
  25. [23]. Caughey G, “Comorbid Diabetes and COPD. Impact of corticosteroid use on diabetes complications” E p i d e m i o l o g y / H e a l t h S e r v i c e s R e s e a r c h O R I G I N A L A R T I C L E. Diabetes Care 36, 2013, 3009–3014.
  26. [24]. Tanushi H, “Calculating Prevalence of Comorbidity and Comorbidity Combinations with Diabetes in Hospital Care in Sweden Using a Health Care Record Database”
  27. [25]. Medved V, “THE COMORBIDITY OF DIABETES MELLITUS AND PSYCHIATRIC DISORDER” PsychiatriaDanubina, 21(4), 2009, 585–588.
  28. [26]. Struijs J, “Comorbidity in patients with diabetes mellitus: Impact on medical health care utilization”.